BioCentury | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights...
...assay as a companion diagnostic to identify ovarian cancer patients who may best respond to Morphotek's...
...with carboplatin plus taxane to treat relapsed, platinum-sensitive ovarian cancer in a Phase III trial. Morphotek...
BioCentury | Oct 10, 2016
Company News

Eisai, Eurofarma Laboratorios deal

...Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized...
...first relapse in patients with low levels of mucin 16 ( MUC16 ; CA125 ). Morphotek...
BioCentury | Dec 21, 2015
Company News

Eisai, University of Gothenburg deal

...Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research...
BioCentury | Dec 14, 2015
Company News

Eisai, Blaze Bioscience deal

...Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin...
...activated epithelial cells. It has completed a Phase II trial in patients with recurrent glioma. Morphotek...
...the technology for its pipeline, said it will determine specific indications for the chlorotoxin derivative. Morphotek...
BioCentury | Dec 7, 2015
Clinical News

Amatuximab: Phase II started

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg...
BioCentury | Apr 6, 2015
Clinical News

Farletuzumab: Phase II started

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg...
BioCentury | Jun 30, 2014
Company News

Eisai, Sorrento deal

...Eisai’s Morphotek Inc. subsidiary and Sorrento’s Concortis Biosystems Inc. subsidiary partnered to generate antibody-drug conjugates (ADCs) based...
...antibody-drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutics using Concortis’ ADC technology. Morphotek...
...research fees and is eligible to receive up to $50 million in milestones, plus royalties. Morphotek...
BioCentury | Oct 14, 2013
Clinical News

MORAb-004: Phase I started

...Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to...
...IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek...
BioCentury | Jan 21, 2013
Clinical News

Farletuzumab: Preliminary Phase III data

...in ovarian cancer based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....
BioCentury | Jan 15, 2013
Clinical News

Eisai's farletuzumab misses in ovarian cancer

...strategy for farletuzumab based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....
Items per page:
1 - 10 of 113
BioCentury | Oct 27, 2017
Company News

Fujirebio developing companion diagnostic for Morphotek's farletuzumab

...The Morphotek Inc. subsidiary of Eisai Co. Ltd. (Tokyo:4523) granted Fujirebio Inc. (Tokyo, Japan) exclusive, worldwide rights...
...assay as a companion diagnostic to identify ovarian cancer patients who may best respond to Morphotek's...
...with carboplatin plus taxane to treat relapsed, platinum-sensitive ovarian cancer in a Phase III trial. Morphotek...
BioCentury | Oct 10, 2016
Company News

Eisai, Eurofarma Laboratorios deal

...Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized...
...first relapse in patients with low levels of mucin 16 ( MUC16 ; CA125 ). Morphotek...
BioCentury | Dec 21, 2015
Company News

Eisai, University of Gothenburg deal

...Eisai’s Morphotek Inc. subsidiary partnered with the Targeted Alpha Therapy (TAT) Group at the university to research...
BioCentury | Dec 14, 2015
Company News

Eisai, Blaze Bioscience deal

...Eisai’s Morphotek Inc. subsidiary granted Blaze an exclusive, worldwide license to develop and commercialize a tumor-targeting chlorotoxin...
...activated epithelial cells. It has completed a Phase II trial in patients with recurrent glioma. Morphotek...
...the technology for its pipeline, said it will determine specific indications for the chlorotoxin derivative. Morphotek...
BioCentury | Dec 7, 2015
Clinical News

Amatuximab: Phase II started

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II ARTEMIS trial to evaluate 5 mg/kg...
BioCentury | Apr 6, 2015
Clinical News

Farletuzumab: Phase II started

...Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg...
BioCentury | Jun 30, 2014
Company News

Eisai, Sorrento deal

...Eisai’s Morphotek Inc. subsidiary and Sorrento’s Concortis Biosystems Inc. subsidiary partnered to generate antibody-drug conjugates (ADCs) based...
...antibody-drug conjugates (ADCs) based on a Morphotek antibody linked to chemotherapeutics using Concortis’ ADC technology. Morphotek...
...research fees and is eligible to receive up to $50 million in milestones, plus royalties. Morphotek...
BioCentury | Oct 14, 2013
Clinical News

MORAb-004: Phase I started

...Eisai's Morphotek Inc. subsidiary said the Children's Oncology Group began an open-label, U.S. Phase I trial to...
...IV MORAb-004 once weekly in about 65 pediatric patients with recurrent or refractory solid tumors. Morphotek...
BioCentury | Jan 21, 2013
Clinical News

Farletuzumab: Preliminary Phase III data

...in ovarian cancer based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....
BioCentury | Jan 15, 2013
Clinical News

Eisai's farletuzumab misses in ovarian cancer

...strategy for farletuzumab based on discussion with external experts and health authorities. In 2011, Eisai's Morphotek Inc....
Items per page:
1 - 10 of 113